Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
72,987,327
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
28,007,948
-
Shares change
-
-1,516,895
-
Total reported value, excl. options
-
$99,996,757
-
Value change
-
-$11,520,766
-
Put/Call ratio
-
25100%
-
Number of buys
-
40
-
Number of sells
-
40
-
Price
-
$3.47
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q1 2025
As of 31 Mar 2025 Lexeo Therapeutics, Inc. - Common Stock (LXEO) had 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 28,007,948 shares of stock of the company.
Largest 10 holders included JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, BlackRock, Inc., Affinity Asset Advisors, LLC, Omega Fund Management, LLC, Blackstone Inc., Vestal Point Capital, LP, Novo Holdings A/S, VANGUARD GROUP INC, and Point72 Asset Management, L.P..
This table shows 88 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.